chevron_leftBack
As of 24 April 2025, Precipio, Inc. has a market cap of $11.58M USD, ranking #32452 globally and #4625 in the United States. It ranks #3251 in the Healthcare sector, and #167 in the Diagnostics & Research industry.
Key Stats
Market Cap
$11.58MUSD
Enterprise Value
$11.45MUSD
Revenue (TTM)
$18.53MUSD
EBITDA (TTM)
-$2.92MUSD
Net Income (TTM)
-$4.29MUSD
EBITDA Margin
-16%
Profit Margin
-23%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ilan Danieli
open_in_new
Employees
60
Website
precipiodx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 41% | 40% | 14% | 16% | 20% | 22% |
Upcoming Earnings
Earnings Date
Tue, May 13
Earnings Time
bedtime
After Close
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PRPO
Precipio Inc
ISIN: US74019L6020
Shares Out.:
Shares Outstanding:
1.504M1
Shares Float:
1.285M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.70 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
